Cyto-Facto Inc. announced that it has received ¥1.2 billion in funding from MPower Partners GP Limited, Asahi Kasei Corporation, FUJIFILM Holdings Corporation, Sumitomo Corporation
Cyto-Facto Inc. announced that it has received ¥1,200 million in a round of funding on June 13, 2025. The transaction included participation from returning investors, MPower Partners GP Limited, Asahi Kasei Corporation, new investors, FUJIFILM Holdings Corporation and Sumitomo Corporation. The company has issued common shares through third party allotment method and has raised ¥2,700 million in its funding till date.
Fujifilm Holdings Corp is a Japan-based company engaged in the healthcare, materials, business innovation, and imaging businesses. The Company operates through four business segments. The Healthcare segment develops, manufactures, sells, and services medical system equipment, contract manufacturing and development of biopharmaceuticals, drug discovery support materials such as cells, culture media, and reagents, pharmaceuticals, cosmetics, and supplements. The Materials segment develops, manufactures, sells, and services electronic materials, display materials, industrial materials, fine chemicals, graphic communication system materials, and inkjet materials. The Business Innovation segment develops, manufactures, sells, and services digital multifunction devices, solutions, and services. The Imaging segment develops, manufactures, sells, and services instant photo systems, color films, color paper, services, and equipment for photo printing, digital cameras, and optical devices.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Cyto-Facto Inc. announced that it has received ¥1.2 billion in funding from MPower Partners GP Limited, Asahi Kasei Corporation, FUJIFILM Holdings Corporation, Sumitomo Corporation
